ACT now, ACT together to accelerate the end of the COVID-19 crisis
COVID-19 has claimed >2 million lives, with >100 million confirmed cases.
ACT-Accelerator made a real difference in 2020, laying the groundwork for **3 robust lines of defense** against COVID-19 globally in 2021

**Vaccines:** COVID-19 infection can be prevented everywhere

COVAX Facility & products have transformed the outlook for vaccination, with the capacity to distribute **>2Bn vaccine doses in 190 countries & economies**

**Tests:** COVID-19 disease can now be detected anywhere

New, affordable & high-quality Rapid Diagnostics (RDTs) transform our capacity to detect infection anywhere, with access to **>375 m low-cost tests for LMICs**

**Treatment:** life-threatening illness can be treated anywhere

Dexamethasone, the first and only proven therapy for severe COVID-19 has transformed our ability to save lives, with global guidance and an urgent stockpile of **2.9 m courses**

---

**Equitable Access:** crucial investments to ensure access & stimulate update, everywhere

**Global Access & Allocation** Framework & COVAX Mechanisms

**Catalytic health systems support** to deliver new products & PPE
Many generous supporters have contributed to ACT Accelerator success

**ACT-A contributions** – in % of total commitments, as of 3 February 2021

US$ 6 billion additional for vaccine procurement & delivery is being finalized with the United States

Note: all financial commitments can be accessed at [https://www.who.int/publications/m/item/access-to-covid-19-tools-tracker](https://www.who.int/publications/m/item/access-to-covid-19-tools-tracker).

1. US$ 6 billion include $470m contributed by the Diagnostics Consortium to procure automated and manual molecular tests for LMICs
2. Excluding US$ 267m by donors to the Global Fund COVID-19 Response Mechanism and redistributed to ACT-A pillars
3. Contributions <US$ 20m
3 big shifts inform the 2021 ACT-A Strategy & Budget

We have entered the **era of COVID-19 vaccines**

**Viral variants** are emerging with increasingly concerning characteristics

**International collaboration is increasingly fragmented** & underinvesting in global solutions

A strong global, integrated and agile response is crucial: scaling up tools while adapting to an evolving context
ACT-Accelerator is releasing a new, prioritized & integrated strategy for 2021
In 2021 ACT-A has four strategic priorities, driving for equity in the delivery of COVID-19 tools, while continuously improving these tools.

1. Rapidly scale-up delivery of >2 B vaccine doses with COVAX Facility
2. Bolster R&D, evaluation & regulatory pathways to optimize products & address variants
3. Stimulate rapid & effective uptake of tests, therapeutics & PPE in LICs/LMICs
4. Ensure robust supply pipeline of essential tests, therapeutics & PPE for LICs/LMICs

Pillar-specific priorities & deliverables underpin the ACT-Accelerator’s 4 cross-cutting, strategic priorities.
US$27.2 Bn is needed for ACT-Accelerator Strategic Priorities in 2021

1. Rapidly scale-up delivery of >2 B doses of vaccine through the COVAX Facility

2. Bolster R&D, evaluation & regulatory pathways, to optimize products & also address variants

3. Stimulate rapid & effective uptake of tests, treatments & PPE in LIC/LMICs

4. Ensure robust supply pipeline of essential tests, treatments & PPE for LICs/LMICs

US$ 27.2 billion

- $6.4 billion
- $13.2 billion
- $5.8 billion
- $1.8 billion
The ACT-Accelerator has built a detailed view of its agency-specific deliverables & funding needs for 2021
COVID-19 is an unstable international crisis

A global solution is essential to recovery

ACT Accelerator now has the tools & access platforms

Scaled multilateral response now required
Working slides (backup)
**ACT-Accelerator needs are catalytic within broader COVID-19 requirements**

**Indicative estimates for an expanded agenda**

- Expanded R&D to address variants ($4 Bn)
- Expanded coverage to enhance control ($26 Bn)$\textsuperscript{1}
  - Vaccine coverage from 20% to 80% in the LICs/LMICs
  - Testing in LICs/LMICs raised to 90% of HICs rates
  - Treatment coverage raised in proportion to testing

---

$\textsuperscript{1}$ procurement estimates only
Pillar-specific priorities for 2021

**Vaccines**
1. Ensure equitable access and fair allocation
2. Ensure delivery at scale of 2bn doses & provide country support
3. Accelerate further development of safe, efficacious and programmatically-optimized vaccines to address new risks

**Diagnostics**
1. Secure equitable access to tests: procurement of 900 mn tests
2. Stimulate rapid & effective uptake in countries
3. Drive development and at-scale availability of affordable, transformative, digitally-integrated tests

**Therapeutics**
1. Intensify research efforts: develop clinical pipeline & broaden portfolio, incl. combinations
2. Ensure market readiness and access & support countries in optimizing clinical care
3. Drive successful uptake and scaled procurement of available therapeutics, incl. O₂

**Health Systems Connector**
1. Contribute to the identification of key health systems bottlenecks in countries
2. Support countries to address the health system bottlenecks or weaknesses identified
3. Accelerate the availability of PPE as high priority commodity
**Pledges & Cost Adjustments** have brought the ACT-Accelerator US$ 38.1 billion budget to a gap of US$ 27.2 billion for 2021

*ACT-A funding gap*, in USD billion

- Not yet allocated to pillars
- Vaccines
- Therapeutics
- Diagnostics
- Health Systems

<table>
<thead>
<tr>
<th>Category</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACT-A budget as of September 2020</td>
<td>38.1</td>
</tr>
<tr>
<td>Cost adjustments as of November 2020</td>
<td>4.9</td>
</tr>
<tr>
<td>Contributions to ACT-A as of November 2020</td>
<td>4.7</td>
</tr>
<tr>
<td>ACT-A funding gap as of November 2020</td>
<td>28.4</td>
</tr>
<tr>
<td>Cost adjustments as of February 2021</td>
<td>+3.6</td>
</tr>
<tr>
<td>Contributions to ACT-A Nov 20 – Feb 21¹</td>
<td>-4.6</td>
</tr>
<tr>
<td>ACT-A funding gap as of February 2021²</td>
<td>27.2</td>
</tr>
</tbody>
</table>

1. Includes US$ 322 million not yet allocated to Pillars and US$ 100 million applied against 2020 costs
2. US$ 0.8 billion of procurement need for Oxygen moved from the Health Systems Connector to the Therapeutics Pillar

US$ 27.2 billion not including:
- US$ 322 million not yet allocated to pillars
- US government US$ 4 billion funding for Vaccine delivery and procurement still under negotiation

Last update: 03 Feb 2021
## ACT-A funding gap by Pillar & Strategic Priority, 2021

### by Pillar
USD billion

<table>
<thead>
<tr>
<th></th>
<th>Q1/Q2 2021</th>
<th>Q3/Q4 2021</th>
<th>Total 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnostics</td>
<td>1.9</td>
<td>7.0</td>
<td>8.9</td>
</tr>
<tr>
<td>Therapeutics</td>
<td>1.4</td>
<td>1.8</td>
<td>3.2</td>
</tr>
<tr>
<td>Vaccines</td>
<td>7.8</td>
<td>&lt;0.1</td>
<td>7.8</td>
</tr>
<tr>
<td>Health Systems Connector</td>
<td>3.2</td>
<td>4.3</td>
<td>7.4</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>14.2</strong></td>
<td><strong>13.1</strong></td>
<td><strong>27.2</strong></td>
</tr>
</tbody>
</table>

### by Strategic Priority
USD billion

<table>
<thead>
<tr>
<th></th>
<th>Q1/Q2 2021</th>
<th>Q3/Q4 2021</th>
<th>Total 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Rapidly scale delivery of 2 billion vaccines doses through COVAX</td>
<td>6.4</td>
<td>&lt;0.1</td>
<td>6.4</td>
</tr>
<tr>
<td>2. Bolster R&amp;D, product evaluation &amp; regulatory pathways</td>
<td>1.6</td>
<td>0.2</td>
<td>1.8</td>
</tr>
<tr>
<td>3. Enhance use of diagnostics (Dx), therapeutics (Tx) &amp; PPE in LMICs</td>
<td>2.0</td>
<td>3.8</td>
<td>5.8</td>
</tr>
<tr>
<td>4. Ensure robust supply pipeline of essential Dx, Tx &amp; PPE for LMICs</td>
<td>4.2</td>
<td>9.0</td>
<td>13.2</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>14.2</strong></td>
<td><strong>13.1</strong></td>
<td><strong>27.2</strong></td>
</tr>
</tbody>
</table>

Note: numbers are rounded to closest figure

Last update: 03 Feb 2021